Brivaracetam (BRV) is a high-affinity synaptic vesicle glycoprotein 2A ligand with fast brain penetration, rapid onset of action and intravenous (IV) formulation, suggesting a potentially use in emergency setting [1]. The role of BRV in patients with genetic generalized epilepsy (GGE) presenting with absence status epilepticus (ASE) is currently limited [1,2], and further experiences are required to warrant recommendation in this emergency situation.
24
MAY
MAY
0